Ma et al. (87) discovered that transcriptional factor myocyte enhancer factor 2D (MEF2D) was overexpressed in sorafenib-resistant HCC cell lines and HCC specimens, indicating a poor prognosis for sorafenib-treated HCC patients. The gene discussed is MEF2D; the disease is hepatocellular carcinoma.